ESPE Abstracts (2021) 94 P2-276

ESPE2021 ePoster Category 2 Growth hormone and IGFs (31 abstracts)

Growth Hormone Resistance; The Iraqi experience

Ali Al-Jumaili

Consultant Paediatric Endocrinologist and Diabetes, Director of Paediatric Endocrinology and Diabetes Center for Paediatrics, Central Teaching Hospital for Paediatrics, Baghdad, Iraq

Introduction: Primary growth hormone resistance or growth hormone insensitivity syndrome (Laron syndrome) is an autosomal recessive disorder caused by deletions or mutations in the growth hormone receptor gene or by post receptor defects. Laron is characterized by a clinical appearance of sever growth hormone deficiency with high levels of growth hormone in contrast to low insulin-like growth factor 1 values and in this cases are refractory to both endogenous and exogenous growth hormone treatment with recombinant human insulin-like growth factor-1 (rhIGF-1).

Case Presentation: We describe two Iraqi cases with Laron syndrome: The first case; a 10-year old female child who presented with postnatal growth failure and hypoglycemic seizures. The second case; a 5-year old male child who is the son of the cousin of the first case Presented with postnatal growth failure. Consanguinity, positive for both families as for the patients.

Evaluation of both cases: Revealed sever short stature, the classic features of growth hormone deficiency (midfacial hypoplasia, frontal prominence, saddle nose, flat nasal bridge, high pitched voice, dental caries, poor dentition).

Measurements: For the first case; weight 11kg, height 79cm both they were far below the 3rd centile (-10.6 SDS) . Bone age 4 year according to RUS atlas. For the second case, his weight 10 kg, height 72cm (-7.6 SDS) bone age 4 year.

Investigations: Disclosed high plasma GH levels and low IGF-1 in both cases the rest of investigations were normal.

Conclusion: From the clinical findings in the context of typical phenotype of growth hormone deficiency along with elevated GH level and low IGF-1 confirmed the diagnosis of growth hormone insensitivity syndrome (Laron syndrome). Genetic testing could not be done because of unavailability in our country also specific therapy in the form of recombinant IGF-1 not available

Volume 94

59th Annual ESPE (ESPE 2021 Online)

22 Sep 2021 - 26 Sep 2021

European Society for Paediatric Endocrinology 

Browse other volumes

Article tools

My recent searches

No recent searches.

My recently viewed abstracts